{"url":"https://newsforagent.com/news/2026-11-05/bausch-lomb-q3-revenue-leverage","markdown_url":"https://newsforagent.com/news/2026-11-05/bausch-lomb-q3-revenue-leverage.md","title":"Bausch + Lomb Q3 Revenue Rises 8% to $1.375 Billion","headline":"Bausch + Lomb Posts $1.375 Billion Q3 Revenue and Cuts Net Leverage to 4.1x","description":"Bausch + Lomb grew Q3 2026 revenue 8% on a constant-currency basis to $1.375 billion and cut net leverage to 4.1x from 5.7x a year earlier.","section":"Earnings & Results","published_at":"2026-11-05T00:55:59+00:00","modified_at":"2026-11-05T00:55:59+00:00","author":"News Desk","key_takeaways":["Bausch + Lomb reported Q3 2026 revenue of $1.375 billion, up 8% on a constant-currency basis.","Net leverage fell to 4.1x from 5.7x a year earlier, with operating cash flow of $233 million in the quarter.","Premium intraocular lens growth approached 70% in the quarter, and full-year revenue and profit targets were raised."],"companies":[{"name":"Bausch & Lomb","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000jw1/bausch-lomb","website":"http://www.bausch.com"}],"source":{"publisher":"The Motley Fool","title":"Bausch + Lomb: 3 Key Takeaways for Long-Term Investors","url":"https://www.fool.com/earnings/takeaways/2026/11/04/bausch-lomb-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001"},"other_sources":[],"tags":["Earnings & Results","Bausch & Lomb"],"body_markdown":"[Bausch](https://akta.pro/company-profiles/0000jw1/bausch-lomb) + Lomb reported third-quarter 2026 revenue of $1.375 billion, up 8% on a constant-currency basis, on its October 28, 2026 earnings call. [The Motley Fool](https://www.fool.com/earnings/takeaways/2026/11/04/bausch-lomb-3-key-takeaways-for-long-term-investors/?source=iedfolrf0000001) covered the call. The eye health company sells prescription pharmaceuticals, contact lenses, surgical devices and over-the-counter eye care products in more than 50 countries.\n\n## Bausch + Lomb's Margin and Debt Progress\n\nAdjusted EBITDA expanded as sales of higher-margin products grew faster than operating expenses. \"Over the last 4 quarters, we have consistently achieved strong revenue growth while expanding profitability at an even faster rate,\" said Tom Appio, Chairman of the Board and Interim Chief Executive Officer.\n\nOperating cash flow reached $233 million in the quarter, which the company used to pay down debt. \"Our strong performance drove net leverage down from 5.7x a year ago to 4.1x at the end of the third quarter,\" said Osama A. Eldessouky, Chief Financial Officer. Eldessouky said the company is \"increasingly confident\" in reaching its 3.5x target.\n\nPremium intraocular lenses and prescription dry eye therapies lifted the product mix and gross margins. \"Reported growth in the quarter approached 70% with our premium offerings continuing to gain traction,\" Appio said of the surgical segment.\n\n## Bausch + Lomb's Raised 2026 Outlook\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Bausch + Lomb raised its 2026 full-year revenue guidance to $5.420–$5.520 billion, representing 5–7% constant currency growth, with adjusted EBITDA guidance of $1.010–$1.060 billion. The same records show full-year 2025 revenue of $5.101 billion, up 6% year-over-year, and Q1 2026 revenue of $1.244 billion, up 9.4% year-over-year.\n\n## Bausch + Lomb's Dry AMD and Refinancing Steps\n\nOn October 6, 2026, Bausch + Lomb announced progress on BL1243 (tonabersat), an oral treatment for dry AMD, after a constructive FDA meeting, [Stock Titan](https://akta.pro/news-signals) reported. The FDA supported the initial study design, and results are expected to support Phase 2 advancement barring unexpected findings.\n\nIn January 2026, Bausch + Lomb completed a refinancing of its outstanding Term B loans through a new credit agreement totaling over $2.8 billion, extending maturity to January 15, 2031 and reducing applicable margins on new loans, according to the same records.\n\n## What Bausch + Lomb Guides Next\n\nBausch + Lomb's raised 2026 guidance puts full-year revenue at $5.420–$5.520 billion and adjusted EBITDA at $1.010–$1.060 billion. Management said it is monitoring research pipeline progress, operating expense efficiency and debt-reduction discipline.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}